A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
Trial ID or NCT#
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
- - Diagnosis of metastatic renal cell carcinoma with confirmed CD70 expression - Previously treated with at least 1 tyrosine kinase inhibitor (TKI) - Measurable disease - Eastern Cooperative Oncology Group performance status 0 or 1 - Adequate lung and renal function
- - Prior treatment with anti-CD70-directed therapy - Received more than one prior treatment with an mTOR inhibitor
Contact us to find out if this trial is right for you.
Cancer Clinical Trials Office
View on ClinicalTrials.gov